Large gap with delayed quotes
|
Last quote
10/16/2026
-
02:00:00
|
Bid
10/16/2026 -
11:56:38
|
Bid Volume |
Ask
10/16/2026 -
11:56:38
|
Ask Volume |
|---|---|---|---|---|
|
18.34
+0.47
(
+2.63% )
|
18.20
|
100 |
20.19
|
100 |
Analysis date: 13.10.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 22.09.2026.
Quality
Very weak
Very weak
One star since 09.10.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 09.10.2026 at a price of 19.45.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 01.09.2026.
4wk Rel Perf
-14.69%
-14.69%
The four-week dividend-adjusted underperformance versus SP500 is 14.69%.
Risk
High
High
High, no change over 1 year.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.19%.
Mkt Cap in $bn
3.03
3.03
With a market capitalization between $2 & $8bn, DENALI THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.48
0.48
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-10.07
-10.07
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
4.78%
4.78%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
18
18
Over the last seven weeks, an average of 18 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
172
172
For 1% of index variation, the stock varies on average by 1.72%.
Correlation
0.39
0.39
Stock movements are strongly independent of index variations.
Value at Risk
4.59
4.59
The value at risk is estimated at USD 4.59. The risk is therefore 24.92%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.11.2020
27.11.2020